NeuroPace Q2 2024 GAAP EPS $(0.26) Beats $(0.31) Estimate, Sales $19.256M Beat $18.297M Estimate
Portfolio Pulse from Benzinga Newsdesk
NeuroPace (NASDAQ:NPCE) reported Q2 2024 GAAP EPS of $(0.26), beating the $(0.31) estimate. Sales were $19.256M, surpassing the $18.297M estimate and showing a 16.63% increase from last year's $16.510M.
August 13, 2024 | 8:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeuroPace reported better-than-expected Q2 2024 earnings and sales, with EPS of $(0.26) beating the $(0.31) estimate and sales of $19.256M surpassing the $18.297M estimate. Sales increased by 16.63% YoY.
The better-than-expected earnings and sales figures are likely to positively impact NPCE's stock price in the short term. Beating both EPS and sales estimates indicates strong performance and growth, which is favorable for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100